Mer­ck spells out ac­cess, en­vi­ron­men­tal goals in lat­est ESG re­port

Ac­cess is a key theme in Mer­ck’s lat­est en­vi­ron­men­tal, so­cial and gov­er­nance (ESG) progress re­port, as the phar­ma gi­ant touts a deal to pro­vide more than 91 mil­lion dos­es of its hu­man pa­pil­lo­mavirus vac­cine to low­er-in­come coun­tries through 2025.

The news comes as child­hood HPV vac­ci­na­tion rates have tak­en a nose­dive amid the pan­dem­ic. Mer­ck re­cent­ly un­veiled a new HPV cam­paign ad­dress­ing the de­cline in the US. The lat­est deal, how­ev­er, ap­plies to Gavi-sup­port­ed coun­tries, which to­taled 57 in 2020 ac­cord­ing to the or­ga­ni­za­tion’s web­site.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER